Latest Revenue Guidance News

Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Amaero has completed commissioning its second advanced atomizer at its Tennessee facility, reinforcing its production capacity and reaffirming strong revenue visibility for FY2026. The company’s strategic investments position it as a key domestic supplier in the US advanced manufacturing sector.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Motio Limited has upgraded its FY25 revenue and EBITDA guidance following unexpectedly strong trading conditions after the Federal Election, driven by a surge in national and programmatic advertising.

Saunders International announces the planned resignation of CEO Mark Benson by year-end alongside a notable downgrade in FY25 revenue and earnings guidance due to project delays and weather disruptions.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Austin Engineering has raised its FY25 revenue guidance to $370 million, driven by strong growth in the Americas, but has lowered its EBIT forecast due to operational challenges in Chile.

Findi Limited has reported record FY25 financial results, exceeding revenue guidance and expanding its ATM and digital financial services footprint across India. The company is advancing towards a Payments Bank license and plans an IPO of its Indian subsidiary by the end of 2026.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

Propel Funeral Partners has released its FY25 financial guidance projecting steady revenue growth despite temporary industry volume contraction, alongside announcing the upcoming retirement of its Managing Director and Co-Founder.

Credit Clear Limited confirms it remains on track to meet its FY25 earnings guidance, buoyed by strong client growth and cost-cutting measures, even as revenue forecasts are revised downward due to timing delays.